Oxidized LDL-induced angiogenesis involves sphingosine 1-phosphate: Prevention by anti-S1P antibody

British Journal of Pharmacology

Volumn 172, Issue 1, 2015, Pages 106-118

  Camaré, Caroline ^a,b   Trayssac, Magali ^a,b   Garmy Susini, Barbara ^a,c   Mucher, Elodie ^a,b   Sabbadini, Roger ^d   Salvayre, Robert ^a,b   Negre Salvayre, Anne ^a,b  

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

^d Biology Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOGENESIS INHIBITOR; CD36 ANTIGEN; DIMETHYLSPHINGOSINE; MATRIGEL; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHOTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; SPHINGOMAB; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHOLIPID; N,N-DIMETHYLSPHINGOSINE; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CAPILLARY ENDOTHELIAL CELL; CAPILLARY TUBE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CELL MOTION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELL MOVEMENT; HUMANS; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SPHINGOSINE;

EID: 84919682587     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12897     Document Type: Article

References (64)

1. Adachi H, Tsujimoto M, (2006). Endothelial scavenger receptors. Prog Lipid Res 45: 379-404.
2. Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O, (2008). Sphingosine kinase 1: a new modulator of HIF-1-alpha during hypoxia in human cancer cells. Cancer Res 68: 8635-8642.
3. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683-690.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
8. Augé N, Nègre-Salvayre A, Salvayre R, Levade T, (2000). Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 39: 207-229.
9. Augé N, Nikolova-Karakashian M, Carpentier S, Parthasarathy S, Nègre-Salvayre A, Salvayre R, et al. (1999). Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized LDL in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 274: 21533-21538.
10. Bergelin N, Löf C, Balthasar S, Kalhori V, Törnquist K, (2010). S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology 151: 2994-3005.
11. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, et al. (2006). Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 99: 900-908.
12. Carmeliet P, Jain RK, (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
13. Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT, et al. (2000). Oxidized LDL inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 101: 171-177.
14. Cinq-Frais C, Coatrieux C, Grazide MH, Hannun YA, Nègre-Salvayre A, Salvayre R, et al. (2013). A signaling cascade mediated by ceramide, src and PDGFRβ coordinates the activation of the redox-sensitive neutral sphingomyelinase-2 and sphingosine kinase-1. Biochim Biophys Acta 1831: 1344-1356.
15. Daiber A, (2010). Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 1797: 897-906.
16. Dandapat A, Hu C, Sun L, Mehta JL, (2007). Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 27: 2435-2442.
17. Daum G, Grabski A, Reidy MA, (2009). Sphingosine 1-phosphate: a regulator of arterial lesions. Arterioscler Thromb Vasc Biol 29: 1439-1443.
18. Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, et al. (2003). Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 146: 62-68.
19. Dikalov S, (2011). Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 51: 1289-1301.
20. Escargueil-Blanc I, Salvayre R, Vacaresse N, Jürgens G, Darblade B, Arnal JF, et al. (2001). Mildly oxidized LDL induces activation of platelet-derived growth factor beta-receptor pathway. Circulation 104: 1814-1821.
21. Hannun YA, Obeid LM, (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150.
22. Hla T, (2003). Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47: 401-407.
23. Jiang F, Zhang Y, Dusting GJ, (2011). N ADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 63: 218-242.
24. Khurana R, Simons M, Martin JF, Zachary IC, (2005). Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112: 1813-1824.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al. (2001). Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276: 31780-31785.
27. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. (2003). Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349: 2316-2325.
28. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. (1999). Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99: 301-312.
29. Levitan I, Volkov S, Subbaiah PV, (2010). Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 13: 39-75.
30. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL, (2010). CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest 120: 3996-4006.
31. McDonald RA, Pyne S, Pyne NJ, Grant A, Wainwright CL, Wadsworth RM, (2010). The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia. Br J Pharmacol 159: 543-553.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Michel JB, Virmani R, Arbustini E, Pasterkamp G, (2011). Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 32: 1977-1985.
34. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V, (2006). Neovascularization in human atherosclerosis. Circulation 113: 2245-2252.
35. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. (2003). Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100: 4736-4741.
36. Murugesan G, Chisolm GM, Fox PL, (1993). Oxidized LDL inhibits the migration of aortic endothelial cells in vitro. J Cell Biol 120: 1011-1019.
37. Negre-Salvayre A, Augé N, Duval C, Robbesyn F, Thiers JC, Nazzal D, et al. (2002). Detection of intracellular reactive oxygen species in cultured cells using fluorescent probes. Methods Enzymol 352: 62-71.
38. Nishi T, Kobayashi N, Hisano Y, Kawahara A, Yamaguchi A, (2014). Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 1841: 759-765.
39. Olivera A, Spiegel S, (1993). Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 365: 557-560.
40. Oskolkova OV, Afonyushkin T, Leitner A, von Schlieffen E, Gargalovic PS, Lusis AJ, et al. (2008). ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response. Blood 112: 330-339.
41. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 67: 519-528.
42. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
43. Pitson SM, (2011). Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 36: 97-107.
44. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, et al. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353.
45. Pyne S, Pyne NJ, (2010). Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-503.
46. Pyne S, Pyne NJ, (2011). Translational aspects of sphingosine-1-phosphate biology. Trends Mol Med 17: 463-472.
47. Rikitake Y, Hirata K, Kawashima S, Ozaki M, Takahashi T, Ogawa W, et al. (2002). Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol 22: 108-114.
48. Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, et al. (2005). HDL prevent the oxidized LDL-induced EGFR activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25: 1206-1212.
49. Sabbadini RA, (2011). Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 162: 1225-1238.
50. Salvayre R, Auge N, Benoist H, Negre-Salvayre A, (2002). Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta 1585: 213-221.
51. Sanson M, Ingueneau C, Vindis C, Thiers JC, Glock Y, Rousseau H, et al. (2008). Oxygen-regulated protein-150 prevents calcium homeostasis deregulation and apoptosis induced by oxidized LDL in vascular cells. Cell Death Differ 15: 1255-1265.
52. Shibuya M, (2008). VEGF-dependent and -independent regulation of angiogenesis. BMB Rep 41: 278-286.
53. Silverstein RL, Febbraio M, (2009). CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behaviour. Sci Signal 2: re3.
54. Spiegel S, Milstien S, (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407.
55. Stocker R, Keaney JF Jr, (2004). Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478.
56. Sukhanov S, Higashi Y, Shai SY, Itabe H, Ono K, Parthasarathy S, et al. (2006). Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase. Circ Res 99: 191-200.
57. Takabe K, Paugh SW, Milstien S, Spiegel S, (2008). 'Inside-out' signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195.
58. Tanimoto T, Jin ZG, Berk BC, (2002). Transactivation of vascular endothelial growth factor receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase. J Biol Chem 277: 42997-43001.
59. Tsimikas S, Miller YI, (2011). Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 17: 27-37.
60. Ushio-Fukai M, Alexander RW, (2004). Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264: 85-97.
61. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. (2006). Validation of an anti-S1P antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225-238.
62. Witztum JL, Steinberg D, (1991). Role of oxidized LDL in atherogenesis. J Clin Invest 88: 1785-1792.
63. You B, Ren A, Yan G, Sun J, (2007). Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia. Diabetes 56: 1445-1453.
64. Yu S, Wong SL, Lau CW, Huang Y, Yu CM, (2011). Oxidized LDL at low concentration promotes in vitro angiogenesis and activates NO synthase through PI3K/Akt/eNOS pathway in human coronary artery endothelial cells. Biochem Biophys Res Commun 407: 44-48.